Liver Ablation: Best Practice

Radiologic Clinics of North America

Volumn 53, Issue 5, 2015, Pages 933-971

  Wells, Shane A ^a   Hinshaw, J Louis ^a   Lubner, Meghan G ^a   Ziemlewicz, Timothy J ^a   Brace, Christopher L ^a,b   Lee, Fred T ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Wisconsin Electric Machines and Power Electronics Consortium   (United States)

Author keywords

Colorectal cancer; HCC; Hepatocellular carcinoma; Microwave; Neuroendocrine cancer; Radiofrequency; Tumor ablation

Indexed keywords

ALCOHOL; FLUORODEOXYGLUCOSE F 18; GADOXETIC ACID; SORAFENIB;

ABLATION THERAPY; ADVANCED CANCER; ANESTHESIA INDUCTION; ARTIFICIAL EMBOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMICAL ABLATION; CHEMOEMBOLIZATION; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOABLATION; ECHOGRAPHY; EVIDENCE BASED PRACTICE; FLUOROSCOPY; HEMANGIOMA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTERMETHOD COMPARISON; IRREVERSIBLE ELECTROPORATION; LIVER ABLATION; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CYST; LIVER METASTASIS; LIVER SURGERY; LIVER TRANSPLANTATION; MICROWAVE THERAPY; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT POSITIONING; PATIENT SELECTION; PERCUTANEOUS ABLATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COLORECTAL TUMOR; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; SECONDARY;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PATIENT SELECTION;

EID: 84940737352     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2015.05.012     Document Type: Review

References (224)

1. Ahmed M., Solbiati L., Brace C.L., et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology 2014, 273(1):241-260.
2. Faroja M., Ahmed M., Appelbaum L., et al. Irreversible electroporation ablation: is all the damage nonthermal?. Radiology 2013, 266(2):462-470.
3. Golberg A., Yarmush M.L. Nonthermal irreversible electroporation: fundamentals, applications, and challenges. IEEE Trans Biomed Eng 2013, 60(3):707-714.
4. Narayanan G., Hosein P.J., Arora G., et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012, 23(12):1613-1621.
5. Goldberg S.N., Kamel I.R., Kruskal J.B., et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002, 179(1):93-101.
6. Takaki H., Yamakado K., Nakatsuka A., et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression. J Vasc Interv Radiol 2007, 18(7):856-861.
7. Yamakado K., Nakatsuka A., Takaki H., et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008, 247(1):260-266.
8. Lewis M.A., Hobday T.J. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol 2012, 2012:973946.
9. Huang G., Lin M., Xie X., et al. Combined radiofrequency ablation and ethanol injection with a multipronged needle for the treatment of medium and large hepatocellular carcinoma. Eur Radiol 2014, 24(7):1565-1571.
10. Hildebrand P., Leibecke T., Kleemann M., et al. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. Eur J Surg Oncol 2006, 32(4):430-434.
11. Poon R.T., Ng K.K., Lam C.M., et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004, 239(4):441-449.
12. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228(1):235-240.
13. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004, 127(6):1714-1723.
14. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129(1):122-130.
15. Lin S.M., Lin C.J., Lin C.C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54(8):1151-1156.
16. Brunello F., Veltri A., Carucci P., et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008, 43(6):727-735.
17. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009, 104(2):514-524.
18. Cho Y.K., Kim J.K., Kim M.Y., et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009, 49(2):453-459.
19. Germani G., Pleguezuelo M., Gurusamy K., et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol 2010, 52(3):380-388.
20. Sala M., Llovet J.M., Vilana R., et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40(6):1352-1360.
21. Lencioni R., Cioni D., Della Pina C., et al. Hepatocellular carcinoma: new options for image-guided ablation. J Hepatobiliary Pancreat Sci 2010, 17(4):399-403.
22. Hong K., Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol 2010, 21(8 Suppl):S179-S186.
23. Goldberg S.N., Hahn P.F., Tanabe K.K., et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis?. J Vasc Interv Radiol 1998, 9(1 Pt 1):101-111.
24. Patterson E.J., Scudamore C.H., Owen D.A., et al. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg 1998, 227(4):559-565.
25. Andreano A., Brace C.L. A comparison of direct heating during radiofrequency and microwave ablation in ex vivo liver. Cardiovasc Intervent Radiol 2013, 36(2):505-511.
26. Lu D.S., Raman S.S., Limanond P., et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003, 14(10):1267-1274.
27. Lu D.S., Raman S.S., Vodopich D.J., et al. Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the "heat sink" effect. AJR Am J Roentgenol 2002, 178(1):47-51.
28. Brace C.L. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences?. Curr Probl Diagn Radiol 2009, 38(3):135-143.
29. Chiang J., Hynes K., Brace C.L. Flow-dependent vascular heat transfer during microwave thermal ablation. Conf Proc IEEE Eng Med Biol Soc 2012, 2012:5582-5585.
30. Kim Y.S., Rhim H., Cho O.K., et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006, 59(3):432-441.
31. Bhardwaj N., Strickland A.D., Ahmad F., et al. A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. Pathology 2009, 41(2):168-172.
32. Schramm W., Yang D., Wood B.J., et al. Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation. Open Biomed Eng J 2007, 1:47-52.
33. Lubner M.G., Brace C.L., Ziemlewicz T.J., et al. Microwave ablation of hepatic malignancy. Semin Intervent Radiol 2013, 30(1):56-66.
34. Yu N.C., Raman S.S., Kim Y.J., et al. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol 2008, 19(7):1087-1092.
35. Huang S., Yu J., Liang P., et al. Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a long-term follow-up. Eur J Radiol 2014, 83(3):552-558.
36. Livraghi T., Meloni F., Solbiati L., et al. Complications of microwave ablation for liver tumors: results of a multicenter study. Cardiovasc Intervent Radiol 2012, 35(4):868-874.
37. Chiang J., Willey B.J., Del Rio A.M., et al. Predictors of thrombosis in hepatic vasculature during microwave tumor ablation of an in vivo porcine model. J Vasc Interv Radiol 2014, 25(12):1965-1971.e2.
38. Jiang J., Brace C., Andreano A., et al. Ultrasound-based relative elastic modulus imaging for visualizing thermal ablation zones in a porcine model. Phys Med Biol 2010, 55(8):2281-2306.
39. Littrup P.J., Ahmed A., Aoun H.D., et al. CT-guided percutaneous cryotherapy of renal masses. J Vasc Interv Radiol 2007, 18(3):383-392.
40. Littrup P.J., Jallad B., Vorugu V., et al. Lethal isotherms of cryoablation in a phantom study: effects of heat load, probe size, and number. J Vasc Interv Radiol 2009, 20(10):1343-1351.
41. Bageacu S., Kaczmarek D., Lacroix M., et al. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol 2007, 33(5):590-596.
42. Bagia J.S., Perera D.S., Morris D.L. Renal impairment in hepatic cryotherapy. Cryobiology 1998, 36(4):263-267.
43. Chapman W.C., Debelak J.P., Wright Pinson C., et al. Hepatic cryoablation, but not radiofrequency ablation, results in lung inflammation. Ann Surg 2000, 231(5):752-761.
44. Dunne R.M., Shyn P.B., Sung J.C., et al. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: a comparison of the safety of cryoablation and radiofrequency ablation. Eur J Radiol 2014, 83(4):632-638.
45. Sheen A.J., Poston G.J., Sherlock D.J. Cryotherapeutic ablation of liver tumours. Br J Surg 2002, 89(11):1396-1401.
46. Sohn R.L., Carlin A.M., Steffes C., et al. The extent of cryosurgery increases the complication rate after hepatic cryoablation. Am Surg 2003, 69(4):317-322. [discussion: 322-3].
47. Washington K., Debelak J.P., Gobbell C., et al. Hepatic cryoablation-induced acute lung injury: histopathologic findings. J Surg Res 2001, 95(1):1-7.
48. Xu K.C., Niu L.Z., He W.B., et al. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World J Gastroenterol 2008, 14(9):1430-1436.
49. Yang Y., Wang C., Lu Y., et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2012, 19(6):674-684.
50. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
51. Venook A.P., Papandreou C., Furuse J., et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl 4):5-13.
52. Davila J.A., Kramer J.R., Duan Z., et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology 2013, 57(5):1858-1868.
53. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126(4):1005-1014.
54. Han K.H., Kim do Y., Park J.Y., et al. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study. J Clin Gastroenterol 2013, 47(6):538-544.
55. Kim W.R., Gores G.J., Benson J.T., et al. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005, 129(2):486-493.
56. Reig M., Darnell A., Forner A., et al. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014, 34(4):444-455.
57. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
58. Abdelaziz A., Elbaz T., Shousha H.I., et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc 2014, 28(12):3429-3434.
59. Ding J., Jing X., Liu J., et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol 2013, 82(9):1379-1384.
60. Groeschl R.T., Pilgrim C.H., Hanna E.M., et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014, 259(6):1195-1200.
61. Iida H., Aihara T., Ikuta S., et al. A comparative study of therapeutic effect between laparoscopic microwave coagulation and laparoscopic radiofrequency ablation. Hepatogastroenterology 2013, 60(124):662-665.
62. Jiao D.C., Zhou Q., Han X.W., et al. Microwave ablation treatment of liver cancer with a 2,450-MHz cooled-shaft antenna: pilot study on safety and efficacy. Asian Pac J Cancer Prev 2012, 13(2):737-742.
63. Poggi G., Montagna B., DI Cesare P., et al. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. Anticancer Res 2013, 33(3):1221-1227.
64. Simo K.A., Sereika S.E., Newton K.N., et al. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: safety and efficacy in comparison with radiofrequency ablation. J Surg Oncol 2011, 104(7):822-829.
65. Takami Y., Ryu T., Wada Y., et al. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci 2013, 20(3):332-341.
66. Vogl T.J., Farshid P., Naguib N.N., et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. Abdom Imaging 2015, [Epub ahead of print].
67. Ziemlewicz T.J., Hinshaw J.L., Lubner M.G., et al. Percutaneous microwave ablation of hepatocellular carcinoma with a gas-cooled system: initial clinical results with 107 tumors. J Vasc Interv Radiol 2015, 26(1):62-68.
68. Cho Y.K., Kim J.K., Kim W.T., et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010, 51(4):1284-1290.
69. Osaki Y., Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res 2015, 45(1):59-74.
70. Livraghi T., Solbiati L., Meloni M.F., et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003, 226(2):441-451.
71. Teratani T., Yoshida H., Shiina S., et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006, 43(5):1101-1108.
72. Kim S.W., Rhim H., Park M., et al. Percutaneous radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder with internally cooled electrodes: assessment of safety and therapeutic efficacy. Korean J Radiol 2009, 10(4):366-376.
73. Komorizono Y., Oketani M., Sako K., et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003, 97(5):1253-1262.
74. Song K.D., Lim H.K., Rhim H., et al. Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study. Radiology 2015, 275:599-608.
75. Kurokohchi K., Watanabe S., Masaki T., et al. Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma. World J Gastroenterol 2005, 11(10):1426-1432.
76. Lee J.M., Lee Y.H., Kim Y.K., et al. Combined therapy of radiofrequency ablation and ethanol injection of rabbit liver: an in vivo feasibility study. Cardiovasc Intervent Radiol 2004, 27(2):151-157.
77. Ahmed M., Weinstein J., Liu Z., et al. Image-guided percutaneous chemical and radiofrequency tumor ablation in an animal model. J Vasc Interv Radiol 2003, 14(8):1045-1052.
78. Sakr A.A., Saleh A.A., Moeaty A.A., et al. The combined effect of radiofrequency and ethanol ablation in the management of large hepatocellular carcinoma. Eur J Radiol 2005, 54(3):418-425.
79. Gasparini D., Sponza M., Marzio A., et al. Combined treatment, TACE and RF ablation, in HCC: preliminary results. Radiol Med 2002, 104(5-6):412-420.
80. Lee M.W., Kim Y.J., Park S.W., et al. Percutaneous radiofrequency ablation of small hepatocellular carcinoma invisible on both ultrasonography and unenhanced CT: a preliminary study of combined treatment with transarterial chemoembolisation. Br J Radiol 2009, 82(983):908-915.
81. Peng Z.W., Zhang Y.J., Liang H.H., et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 2012, 262(2):689-700.
82. Hoffmann R., Rempp H., Syha R., et al. Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma. Eur J Radiol 2014, 83(10):1793-1798.
83. Ginsburg M., Zivin S.P., Wroblewski K., et al. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J Vasc Interv Radiol 2015, 26(3):330-341.
84. Peng Z.W., Chen M.S., Liang H.H., et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol 2010, 36(3):257-263.
85. Zhang Y.J., Liang H.H., Chen M.S., et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007, 244(2):599-607.
86. Fujimori M., Takaki H., Nakatsuka A., et al. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol 2013, 24(5):655-666.
87. Fujimori M., Takaki H., Nakatsuka A., et al. Combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. J Vasc Interv Radiol 2012, 23(12):1622-1628.
88. Kang S.G., Yoon C.J., Jeong S.H., et al. Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study. J Vasc Interv Radiol 2009, 20(12):1570-1577.
89. Ke S., Ding X., Gao J., et al. Solitary huge hepatocellular carcinomas 10 cm or larger may be completely ablated by repeated radiofrequency ablation combined with chemoembolization: initial experience with 9 patients. Mol Med Rep 2012, 5(3):832-836.
90. Shiraishi R., Yamasaki T., Saeki I., et al. Pilot study of combination therapy with transcatheter arterial infusion chemotherapy using iodized oil and percutaneous radiofrequency ablation during occlusion of hepatic blood flow for hepatocellular carcinoma. Am J Clin Oncol 2008, 31(4):311-316.
91. Takaki H., Yamakado K., Uraki J., et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol 2009, 20(2):217-224.
92. Kurokohchi K., Watanabe S., Masaki T., et al. Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. Int J Oncol 2002, 21(3):611-615.
93. Chung H., Kudo M., Minami Y., et al. Radiofrequency ablation combined with reduction of hepatic blood flow: effect of Lipiodol on coagulation diameter and ablation time in normal pig liver. Hepatogastroenterology 2007, 54(75):701-704.
94. Guang C., Kawai N., Sato M., et al. Effect of interval between transcatheter hepatic arterial embolization and radiofrequency ablation on ablated lesion size in a swine model. Jpn J Radiol 2011, 29(9):649-655.
95. Iwamoto T., Kawai N., Sato M., et al. Effectiveness of hepatic arterial embolization on radiofrequency ablation volume in a swine model: relationship to portal venous flow and liver parenchymal pressure. J Vasc Interv Radiol 2008, 19(11):1646-1651.
96. Morimoto M., Numata K., Nozawa A., et al. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. J Vasc Interv Radiol 2010, 21(11):1716-1724.
97. Mostafa E.M., Ganguli S., Faintuch S., et al. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J Vasc Interv Radiol 2008, 19(12):1740-1748.
98. Nakai M., Sato M., Sahara S., et al. Radiofrequency ablation in a porcine liver model: effects of transcatheter arterial embolization with iodized oil on ablation time, maximum output, and coagulation diameter as well as angiographic characteristics. World J Gastroenterol 2007, 13(20):2841-2845.
99. Yamanaka T., Yamakado K., Takaki H., et al. Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas. Jpn J Radiol 2012, 30(7):553-559.
100. Toyoda M., Kakizaki S., Horiuchi K., et al. Computed tomography-guided transpulmonary radiofrequency ablation for hepatocellular carcinoma located in hepatic dome. World J Gastroenterol 2006, 12(4):608-611.
101. Yamakado K., Nakatsuka A., Ohmori S., et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002, 13(12):1225-1232.
102. Liu H.C., Shan E.B., Zhou L., et al. Combination of percutaneous radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: observation of clinical effects. Chin J Cancer Res 2014, 26(4):471-477.
103. Lencioni R., Crocetti L., Petruzzi P., et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008, 49(2):217-222.
104. Kim J.H., Kim P.N., Won H.J., et al. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone. AJR Am J Roentgenol 2014, 203(5):1127-1131.
105. Kelly M.E., Spolverato G., Lê G.N., et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. J Surg Oncol 2015, 111(3):341-351.
106. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27(22):3677-3683.
107. Sharma S., Camci C., Jabbour N. Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg 2008, 15(6):570-580.
108. Lewis A.M., Martin R.C. The treatment of hepatic metastases in colorectal carcinoma. Am Surg 2006, 72(6):466-473.
109. Mavros M.N., de Jong M., Dogeas E., et al. Impact of complications on long-term survival after resection of colorectal liver metastases. Br J Surg 2013, 100(5):711-718.
110. Tanaka K., Adam R., Shimada H., et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003, 90(8):963-969.
111. Sanoff H.K., McLeod H.L. Predictive factors for response and toxicity in chemotherapy: pharmacogenomics. Semin Colon Rectal Surg 2008, 19(4):226-230.
112. Vigano L., Capussotti L., Lapointe R., et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol 2014, 21(4):1276-1286.
113. Dexiang Z., Li R., Ye W., et al. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases. Ann Surg Oncol 2012, 19(9):2860-2868.
114. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007-1016.
115. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013, 14(12):1208-1215.
116. Mitry E., Fields A.L., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008, 26(30):4906-4911.
117. Portier G., Elias D., Bouche O., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006, 24(31):4976-4982.
118. Ruers T., Punt C., Van Coevorden F., et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012, 23(10):2619-2626.
119. Gleisner A.L., Choti M.A., Assumpcao L., et al. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008, 143(12):1204-1212.
120. Agcaoglu O., Aliyev S., Karabulut K., et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg 2013, 37(6):1333-1339.
121. Hammill C.W., Billingsley K.G., Cassera M.A., et al. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol 2011, 18(7):1947-1954.
122. Otto G., Düber C., Hoppe-Lotichius M., et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010, 251(5):796-803.
123. Kim K.H., Yoon Y.S., Yu C.S., et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 2011, 81(1):25-34.
124. Reuter N.P., Woodall C.E., Scoggins C.R., et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?. J Gastrointest Surg 2009, 13(3):486-491.
125. Hur H., Ko Y.T., Min B.S., et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009, 197(6):728-736.
126. Oshowo A., Gillams A., Harrison E., et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003, 90(10):1240-1243.
127. Hamada A., Yamakado K., Nakatsuka A., et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol 2012, 30(7):567-574.
128. Solbiati L., Ahmed M., Cova L., et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012, 265(3):958-968.
129. Veltri A., Sacchetto P., Tosetti I., et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol 2008, 31(5):948-956.
130. Nielsen K., van Tilborg A.A., Meijerink M.R., et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg 2013, 37(6):1340-1347.
131. Gillams A.R., Lees W.R. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiol 2008, 19(5):712-717.
132. Wang X., Sofocleous C.T., Erinjeri J.P., et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013, 36(1):166-175.
133. Rind G., Arnold R., Bosman F.T., et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO classification of tumours of the digestive system 2010, 13. International Agency for Research on Cancer (IARC), Lyon (France). T.F. Bosman, R.H. Hruban, N.D. Theise (Eds.).
134. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000, 190(4):432-445.
135. Chen H., Hardacre J.M., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 1998, 187(1):88-92. [discussion: 92-3].
136. Givi B., Pommier S.J., Thompson A.K., et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006, 140(6):891-897. [discussion: 897-8].
137. Mayo S.C., de Jong M.C., Pulitano C., et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010, 17(12):3129-3136.
138. Glazer E.S., Tseng J.F., Al-Refaie W., et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010, 12(6):427-433.
139. Gedaly R., Daily M.F., Davenport D., et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011, 146(8):953-958.
140. Lang H., Oldhafer K.J., Weimann A., et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997, 225(4):347-354.
141. Le Treut Y.P., Delpero J.R., Dousset B., et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997, 225(4):355-364.
142. Marin C., Robles R., Fernández J.A., et al. Role of liver transplantation in the management of unresectable neuroendocrine liver metastases. Transplant Proc 2007, 39(7):2302-2303.
143. van Vilsteren F.G., Baskin-Bey E.S., Nagorney D.M., et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 2006, 12(3):448-456.
144. Sward C., Johanson V., Nieveen van Dijkum E., et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009, 96(5):517-521.
145. Christante D., Pommier S., Givi B., et al. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008, 144(6):885-893. [discussion: 893-4].
146. Loewe C., Schindl M., Cejna M., et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003, 180(5):1379-1384.
147. de Baere T., Deschamps F., Teriitheau C., et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008, 19(6):855-861.
148. Kennedy A.S., Dezarn W.A., McNeillie P., et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008, 31(3):271-279.
149. Kennedy A., Bester L., Salem R., et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-liver-metastases consensus conference. HPB (Oxford) 2015, 17(1):29-37.
150. Rhee T.K., Lewandowski R.J., Liu D.M., et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008, 247(6):1029-1035.
151. Gaur S.K., Friese J.L., Sadow C.A., et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011, 34(3):566-572.
152. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005, 104(8):1590-1602.
153. Akyildiz H.Y., Mitchell J., Milas M., et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010, 148(6):1288-1293. [discussion: 1293].
154. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
155. Largillier R., Ferrero J.M., Doyen J., et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008, 19(12):2012-2019.
156. Chua T.C., Saxena A., Liauw W., et al. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 2011, 47(15):2282-2290.
157. Singletary S.E., Walsh G., Vauthey J.N., et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003, 8(3):241-251.
158. Ruiterkamp J., Ernst M.F. The role of surgery in metastatic breast cancer. Eur J Cancer 2011, 47(Suppl 3):S6-S22.
159. Pentheroudakis G., Fountzilas G., Bafaloukos D., et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 2006, 97(3):237-244.
160. Dittmar Y., Altendorf-Hofmann A., Schüle S., et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol 2013, 139(8):1317-1325.
161. O'Rourke T.R., Tekkis P., Yeung S., et al. Long-term results of liver resection for non-colorectal, non-neuroendocrine metastases. Ann Surg Oncol 2008, 15(1):207-218.
162. Blanchard D.K., Shetty P.B., Hilsenbeck S.G., et al. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008, 247(5):732-738.
163. Fields R.C., Jeffe D.B., Trinkaus K., et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007, 14(12):3345-3351.
164. Ruiterkamp J., Ernst M.F., van de Poll-Franse L.V., et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 2009, 35(11):1146-1151.
165. Livraghi T., Goldberg S.N., Solbiati L., et al. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 2001, 220(1):145-149.
166. Cui Y., Zhou L.Y., Dong M.K., et al. Ultrasonography guided percutaneous radiofrequency ablation for hepatic cavernous hemangioma. World J Gastroenterol 2003, 9(9):2132-2134.
167. Gao J., Ding X., Ke S., et al. Radiofrequency ablation in the treatment of large hepatic hemangiomas: a comparison of multitined and internally cooled electrodes. J Clin Gastroenterol 2014, 48(6):540-547.
168. Gao J., Ke S., Ding X.M., et al. Radiofrequency ablation for large hepatic hemangiomas: initial experience and lessons. Surgery 2013, 153(1):78-85.
169. Park S.Y., Tak W.Y., Jung M.K., et al. Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation. J Hepatol 2011, 54(3):559-565.
170. Tang X.Y., Wang Z., Wang T., et al. Efficacy, safety and feasibility of ultrasound-guided percutaneous microwave ablation for large hepatic hemangioma. J Dig Dis 2014, [Epub ahead of print].
171. Ziemlewicz T.J., Wells S.A., Lubner M.A., et al. Microwave ablation of giant hepatic cavernous hemangiomas. Cardiovasc Intervent Radiol 2014, 37(5):1299-1305.
172. Liau S.S., Qureshi M.S., Praseedom R., et al. Molecular pathogenesis of hepatic adenomas and its implications for surgical management. J Gastrointest Surg 2013, 17(10):1869-1882.
173. Rhim H., Lim H.K., Kim Y.S., et al. Percutaneous radiofrequency ablation of hepatocellular adenoma: initial experience in 10 patients. J Gastroenterol Hepatol 2008, 23(8 Pt 2):e422-e427.
174. van Vledder M.G., van Aalten S.M., Terkivatan T., et al. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol 2011, 22(6):787-793.
175. Ikeda K., Seki T., Umehara H., et al. Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol 2007, 31(3):485-491.
176. Okusaka T., Okada S., Ueno H., et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002, 95(9):1931-1937.
177. Maeda T., Takenaka K., Taguchi K., et al. Small hepatocellular carcinoma with minute satellite nodules. Hepatogastroenterology 2000, 47(34):1063-1066.
178. Nakazawa T., Kokubu S., Shibuya A., et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007, 188(2):480-488.
179. Liu C.H., Arellano R.S., Uppot R.N., et al. Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression. Eur Radiol 2010, 20(4):877-885.
180. Ke S., Ding X.M., Qian X.J., et al. Radiofrequency ablation of hepatocellular carcinoma sized >3 and
181. Liu Z., Ahmed M., Sabir A., et al. Computer modeling of the effect of perfusion on heating patterns in radiofrequency tumor ablation. Int J Hyperthermia 2007, 23(1):49-58.
182. Mulier S., Ni Y., Jamart J., et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005, 242(2):158-171.
183. Shirabe K., Takenaka K., Gion T., et al. Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br J Surg 1997, 84(8):1077-1080.
184. Smolock A.R., Lubner M.G., Ziemlewicz T.J., et al. Microwave ablation of hepatic tumors abutting the diaphragm is safe and effective. AJR Am J Roentgenol 2015, 204(1):197-203.
185. Li M., Yu X.L., Liang P., et al. Percutaneous microwave ablation for liver cancer adjacent to the diaphragm. Int J Hyperthermia 2012, 28(3):218-226.
186. Kim P.N., Choi D., Rhim H., et al. Planning ultrasound for percutaneous radiofrequency ablation to treat small (
187. Tang Z., Fang H., Kang M., et al. Percutaneous radiofrequency ablation for liver tumors: is it safer and more effective in low-risk areas than in high-risk areas?. Hepatol Res 2011, 41(7):635-640.
188. Kang T.W., Rhim H., Kim E.Y., et al. Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy. Korean J Radiol 2009, 10(1):34-42.
189. Head H.W., Dodd G.D., Dalrymple N.C., et al. Percutaneous radiofrequency ablation of hepatic tumors against the diaphragm: frequency of diaphragmatic injury. Radiology 2007, 243(3):877-884.
190. Hinshaw J.L., Laeseke P.F., Winter T.C., et al. Radiofrequency ablation of peripheral liver tumors: intraperitoneal 5% dextrose in water decreases postprocedural pain. AJR Am J Roentgenol 2006, 186(5 Suppl):S306-S310.
191. Kitchin D., Lubner M., Ziemlewicz T., et al. Microwave ablation of malignant hepatic tumours: intraperitoneal fluid instillation prevents collateral damage and allows more aggressive case selection. Int J Hyperthermia 2014, 30(5):299-305.
192. Kang T.W., Rhim H., Lee M.W., et al. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: comparison of effects of thermal protection and therapeutic efficacy. AJR Am J Roentgenol 2011, 196(4):907-913.
193. Song I., Rhim H., Lim H.K., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol 2009, 19(11):2630-2640.
194. Rhim H., Lim H.K., Kim Y.S., et al. Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: initial experience. AJR Am J Roentgenol 2008, 190(1):91-98.
195. Chen M.H., Yang W., Yan K., et al. Radiofrequency ablation of problematically located hepatocellular carcinoma: tailored approach. Abdom Imaging 2008, 33(4):428-436.
196. Uehara T., Hirooka M., Ishida K., et al. Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. J Gastroenterol 2007, 42(4):306-311.
197. Takaki H., Yamakado K., Nakatsuka A., et al. Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: single-center experience. AJR Am J Roentgenol 2013, 200(3):658-664.
198. Shibata T., Shibata T., Maetani Y., et al. Transthoracic percutaneous radiofrequency ablation for liver tumors in the hepatic dome. J Vasc Interv Radiol 2004, 15(11):1323-1327.
199. de Baere T., Dromain C., Lapeyre M., et al. Artificially induced pneumothorax for percutaneous transthoracic radiofrequency ablation of tumors in the hepatic dome: initial experience. Radiology 2005, 236(2):666-670.
200. Marchal F., Elias D., Rauch P., et al. Biliary lesions during radiofrequency ablation in liver. Study on the pig. Eur Surg Res 2004, 36(2):88-94.
201. Marchal F., Elias D., Rauch P., et al. Prevention of biliary lesions that may occur during radiofrequency ablation of the liver: study on the pig. Ann Surg 2006, 243(1):82-88.
202. Ogawa T., Kawamoto H., Kobayashi Y., et al. Prevention of biliary complication in radiofrequency ablation for hepatocellular carcinoma-Cooling effect by endoscopic nasobiliary drainage tube. Eur J Radiol 2010, 73(2):385-390.
203. Kingham T.P., Karkar A.M., D'Angelica M.I., et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012, 215(3):379-387.
204. Akahane M., Koga H., Kato N., et al. Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 2005, 25(Suppl 1):S57-S68.
205. Ryan E.R., Sofocleous C.T., Schöder H., et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013, 268(1):288-295.
206. Liu F.Y., Yu X.L., Liang P., et al. Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. Int J Hyperthermia 2010, 26(5):448-455.
207. Krucker J., Xu S., Venkatesan A., et al. Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol 2011, 22(4):515-524.
208. Venkatesan A.M., Kadoury S., Abi-Jaoudeh N., et al. Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Radiology 2011, 260(3):848-856.
209. Yu X., Liu F., Liang P., et al. Microwave ablation assisted by a computerised tomography-ultrasonography fusion imaging system for liver lesions: an ex vivo experimental study. Int J Hyperthermia 2011, 27(2):172-179.
210. Minami Y., Kudo M. Ultrasound fusion imaging of hepatocellular carcinoma: a review of current evidence. Dig Dis 2014, 32(6):690-695.
211. Clasen S., Rempp H., Boss A., et al. MR-guided radiofrequency ablation of hepatocellular carcinoma: long-term effectiveness. J Vasc Interv Radiol 2011, 22(6):762-770.
212. Clasen S., Rempp H., Hoffmann R., et al. Image-guided radiofrequency ablation of hepatocellular carcinoma (HCC): is MR guidance more effective than CT guidance?. Eur J Radiol 2014, 83(1):111-116.
213. Lee M.W., Rhim H., Cha D.I., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol 2012, 198(6):1438-1444.
214. Mauri G., Cova L., De Beni S., et al. Real-Time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with us: results in 295 cases. Cardiovasc Intervent Radiol 2015, 38(1):143-151.
215. Rempp H., Clasen S., Pereira P.L. Image-based monitoring of magnetic resonance-guided thermoablative therapies for liver tumors. Cardiovasc Intervent Radiol 2012, 35(6):1281-1294.
216. Song K.D., Lee M.W., Rhim H., et al. Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol 2013, 201(5):1141-1147.
217. Terraz S., Cernicanu A., Lepetit-Coiffé M., et al. Radiofrequency ablation of small liver malignancies under magnetic resonance guidance: progress in targeting and preliminary observations with temperature monitoring. Eur Radiol 2010, 20(4):886-897.
218. Wu B., Xiao Y.Y., Zhang X., et al. Magnetic resonance imaging-guided percutaneous cryoablation of hepatocellular carcinoma in special regions. Hepatobiliary Pancreat Dis Int 2010, 9(4):384-392.
219. Brace C.L., Sampson L.A., Hinshaw J.L., et al. Radiofrequency ablation: simultaneous application of multiple electrodes via switching creates larger, more confluent ablations than sequential application in a large animal model. J Vasc Interv Radiol 2009, 20(1):118-124.
220. Lubner M.G., Brace C.L., Hinshaw J.L., et al. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010, 21(8 Suppl):S192-S203.
221. Fernandes M.L., Lin C.C., Lin C.J., et al. Risk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation. Br J Surg 2009, 96(7):756-762.
222. Claudon M., Dietrich C.F., Choi B.I., et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013, 34(1):11-29.
223. Boas F.E., Do B., Louie J.D., et al. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2015, 26(1):69-73.
224. Liu D., Fong D.Y., Chan A.C., et al. Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk stratification. Radiology 2015, 274(1):133-140.